Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS.

Background: Timely identification of drug-induced Parkinson-like events is essential to improve clinical management and enhance patients' quality of life. However, there is a significant lack of studies addressing these events in real-world settings.

Methods: To bridge this gap, we analyzed adverse event (AE) reports related to Parkinson-like events from the FDA Adverse Event Reporting System (FAERS) database from the first quarter of 2004 to the first quarter of 2024.

O-evolving and ROS-activable nanoparticles for treatment of multi-drug resistant Cancer by combination of photodynamic therapy and chemotherapy.

Herein, a novel nano-system IF7-ROSPCNP, which is O-evolving and reactive oxygen species (ROS)-activable, was developed for enhancing the combination chemotherapy and photodynamic therapy (PDT). The nanoparticles composed of photosensitizers (disulfonated meso-tetraphenylporphine, TPPS2a) and catalase in the inner core, doxorubicin (DOX) in the polymeric shell and functionalized on its surface with IF7 peptide, which specially bind to annexin 1. As confirmed that the structure of IF7-ROSPCNP was able to remain intact under normal physiological conditions.

[Study on effect of electroacupuncture at Hegu (LI 4) on the uterotonic time in parturients of uterus inertia].

Objective: To evaluate the therapeutic effect and applying value of Hegu (LI 4) for inertia of uterus.

Methods: In three centers, 276 cases enrolled were randomly assigned to a western medicine group and an acupuncture and western medicine group. The western medicine group were treated with intravenous drip of oxytocin, and the acupuncture and western medicine group were treated with electroacupuncture at Hego (LI 4) and intravenous drip of oxytocin.